Follow

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer
Radius Research Radius Research

Radius Research

meticulous due diligence. Under the astute leadership of Founder Martin Gagle, the firm has embarked on a mission to demystify the investment landscape, one insightful conversation at a time. Martin hosts a weekly video series, engaging in enlightening discussions with C-suite executives from every corner of the globe, thereby bridging the informational chasm that often exists between companies and potential investors. This initiative not only shines a light on the visions and ventures of seasoned CEOs but also unveils emerging companies poised to make a significant impact in the industry. Radius Research transcends the conventional advisory role by facilitating a platform where ideas exchange hands and trust is the currency. The firm’s offerings are not just robust but come with a stamp of Institutional Quality, ensuring clients are well-equipped with the acumen necessary to navigate the complex financial waters. Through its unwavering commitment to transparency and quality, Radius Research Investments is not just a service provider, but a companion in the investment journey.

This video is produced on behalf of the presenting company. 
Emerging Hybrid Intracoronary Imaging Technologies and Their Applications in Clinical Practice and Research
https://www.jacc.org/doi/abs/10.1016/j.jcin.2024.07.007

Conavi Medical Submits Next Generation Novasight Hybrid Intravascular Imaging System to US FDA for 510(k) Clearance

2025-09-16 16:34 ET - News Release

US FDA 510(k) Submission Follows the Successful Validation Testing with KOLs

FDA 510(k) Clearance Anticipated During H1 2026 and Company Preparing for US Commercial Launch following Clearance

Coronary Intravascular Imaging Market Expected to Grow to over $1 bil USD by 2028
TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, announced that it has submitted its next generation Novasight Hybrid™ IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (“FDA”) for 510(k) clearance for coronary applications.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

This video is produced on behalf of the presenting company.
Emerging Hybrid Intracoronary Imaging Technologies and Their Applications in Clinical Practice and Research
https://www.jacc.org/doi/abs/10.1016/j.jcin.2024.07.007

Conavi Medical Submits Next Generation Novasight Hybrid Intravascular Imaging System to US FDA for 510(k) Clearance

2025-09-16 16:34 ET - News Release

US FDA 510(k) Submission Follows the Successful Validation Testing with KOLs

FDA 510(k) Clearance Anticipated During H1 2026 and Company Preparing for US Commercial Launch following Clearance

Coronary Intravascular Imaging Market Expected to Grow to over $1 bil USD by 2028
TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, announced that it has submitted its next generation Novasight Hybrid™ IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (“FDA”) for 510(k) clearance for coronary applications.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLmRNTkdmM0lfdENF

Conavi Medical (CNVI) Submits Novasight Hybrid Intravascular Imaging System to US FDA for Clearance

Radius Research September 18, 2025 3:44 pm

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer